Jamal Elkhader

  • Citations Per Year
Learn More
Many pathogens infiltrate the body and initiate infection via mucosal surfaces. Hence, eliciting cellular immune responses at mucosal portals of entry is of great interest for vaccine development against mucosal pathogens. We describe a pulmonary vaccination strategy combining Toll-like receptor (TLR) agonists with antigen-carrying lipid nanocapsules(More)
Immunostimulatory agonists such as anti-CD137 and interleukin (IL)-2 have elicited potent antitumor immune responses in preclinical studies, but their clinical use is limited by inflammatory toxicities that result upon systemic administration. We hypothesized that by rigorously restricting the biodistribution of immunotherapeutic agents to a locally(More)
Peter C. DeMuth1,2, Adrienne V. Li1, Peter Abbink3, Jinyan Liu3, Hualin Li3, Kelly A. Stanley3, Kaitlin M. Smith3, Christy L. Lavine3, Michael S. Seaman3, Joshua A. Kramer4, Andrew D. Miller4, Wuhbet Abraham1,2,5, Heikyung Suh1,2,5, Jamal Elkhader1, Paula T. Hammond2,6,7, Dan H. Barouch3,8, and Darrell J. Irvine1,2,7,8,9 1Department of Biological(More)
Immunostimulatory agonists such as anti-CD137 and interleukin (IL)-2 have elicited potent antitumor immune responses in preclinical studies, but their clinical use is limited by inflammatory toxicities that result upon systemic administration. We hypothesized that by rigorously restricting the biodistribution of immunotherapeutic agents to a locally(More)
  • 1